Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis
BURLINGTON, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate, Zilretta (also known as FX006), on blood …